Paper Details

  1. Home
  2. Paper Details

Early effects of tocilizumab in the treatment of moderate to severe active rheumatoid arthritis: a one-week sub-study of a randomised controlled trial (Rapid Onset and Systemic Efficacy [ROSE] Study).

Author: BarafHerbert S B, CurtisJeffrey R, DevenportJenny N, InceAkgun, KavanaughArthur, LepleyDenise M, YaziciYusuf

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Tocilizumab was found to improve patient-reported disease activity, pain and DAS28 score as early as day 7 after the first infusion in patients with rheumatoid arthritis.
Paper Details　
Original Abstract of the Article :
OBJECTIVES: Tocilizumab has demonstrated efficacy in managing rheumatoid arthritis (RA) from week 2 onward. This sub-study assessed effects of tocilizumab plus disease-modifying anti-rheumatic drugs (DMARDs) during the first week of therapy. METHODS: Rapid Onset and Systemic Efficacy was a 24-week,...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/23305631

データ提供：米国国立医学図書館（NLM）

Early Effects of Tocilizumab in the Treatment of Moderate to Severe Active Rheumatoid Arthritis: A One-Week Sub-Study of a Randomized Controlled Trial (Rapid Onset and Systemic Efficacy [ROSE] Study)

The desert of rheumatoid arthritis (RA) research is constantly seeking new and effective treatments to alleviate the debilitating symptoms of this autoimmune disorder. This study explores the early effects of tocilizumab, a monoclonal antibody that targets interleukin-6 (IL-6), in the treatment of moderate to severe active RA. The authors investigate the potential benefits of tocilizumab therapy within the first week of treatment, analyzing patient-reported outcomes, disease activity scores, and inflammatory markers. The research aims to shed light on the rapid onset of action of tocilizumab and its potential to provide early relief for patients with RA.

A Beacon of Hope in the Desert of Rheumatoid Arthritis: The Early Effects of Tocilizumab

This study explores the rapid onset of action of tocilizumab, a monoclonal antibody that targets interleukin-6 (IL-6), in the treatment of moderate to severe active rheumatoid arthritis (RA). The authors' analysis of patient-reported outcomes, disease activity scores, and inflammatory markers suggests that tocilizumab can provide early relief for patients with RA, offering a potential for improved quality of life in the face of this challenging disorder.

Navigating the Desert of Rheumatoid Arthritis: Early Benefits of Tocilizumab

This study highlights the rapid onset of action of tocilizumab in the treatment of moderate to severe active RA. The authors' analysis of patient-reported outcomes, disease activity scores, and inflammatory markers suggests that tocilizumab can provide early relief for patients with RA, offering a potential for improved quality of life in the face of this challenging disorder.

Dr. Camel's Conclusion

This study explores the early effects of tocilizumab, a monoclonal antibody that targets interleukin-6 (IL-6), in the treatment of moderate to severe active rheumatoid arthritis (RA). The authors' analysis of patient-reported outcomes, disease activity scores, and inflammatory markers suggests that tocilizumab can provide early relief for patients with RA, offering a potential for improved quality of life. This research contributes to the ongoing search for effective and rapid-acting therapies in the vast desert of RA research.
Date :
  1. Date Completed 2013-08-13
  2. Date Revised 2021-10-21
Further Info :

Pubmed ID

23305631

DOI: Digital Object Identifier

6244

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.